

Aragen secures \$100 M investment from Quadria Capital

13 January 2025 | News

Investment will fund expansion to meet rising demand for CRDMO services



Aragen, a globally renowned Contract Research, Development and Manufacturing Organisation (CRDMO), has secured a \$100 million investment from Quadria Capital, an Asia healthcare-focused Private Equity fund.

The investment will result in Quadria acquiring a minority stake in Aragen, at an approximate valuation of \$1.4 billion, primarily through a fresh capital infusion, with a small portion from the sale of shares by existing investors.

This funding will support Aragen's strategic expansion of its capabilities and infrastructure, enabling the company to meet the growing demand for outsourcing services from innovators in the US and Europe

With this investment, Quadria joins Goldman Sachs as the second strategic investor in Aragen. This partnership further solidifies Aragen's reputation for delivering high-quality "concept to clinic" and "concept to commercial" services to its global customer base comprising all sectors of health – Human, Animal and Plant. The announcement comes ahead of JPM Week 2025, where Aragen is expected to secure additional outsourcing partnerships.

Manni Kantipudi, CEO, Aragen Life Science said, "Our expanded capabilities will allow us to support the rising demand for integrated discovery and manufacturing services, and, most importantly, help our customers accelerate their programs to market faster and more efficiently."